title: 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells.
abstract: Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcriptional regulator for the protection of cells against oxidative and xenobiotic stresses. Recent studies have demonstrated that high constitutive expression of Nrf2 is observed in many types of cancer cells showing resistance to anti-cancer drugs, suggesting that the suppression of overexpressed Nrf2 could be an attractive therapeutic strategy to overcome cancer drug resistance. In the present study, we aimed to find small molecule compounds that enhance the sensitivity of tumor cells to cisplatin induced cytotoxicity by suppressing Nrf2-mediated defense mechanism. A549 lung cancer cells were shown to be more resistant to the anti-cancer drug cisplatin than HEK293 cells, with higher Nrf2 signaling activity; constitutively high amounts of Nrf2-downstream target proteins were observed in A549 cells. Among the three chalcone derivatives 4-methoxy-chalcone (4-MC), hesperidin methylchalcone, and neohesperidin dihydrochalcone, 4-MC was found to suppress transcriptional activity of Nrf2 in A549 cells but to activate it in HEK293 cells. 4-MC was also shown to down-regulate expression of Nrf2 and the downstream phase II detoxifying enzyme NQO1 in A549 cells. The PI3K/Akt pathway was found to be involved in the 4-MC-induced inhibition of Nrf2/ARE activity in A549 cells. This inhibition of Nrf2 signaling results in the accelerated generation of reactive oxygen species and exacerbation of cytotoxicity in cisplatin-treated A549 cells. Taken together, these results suggest that the small molecule compound 4-MC could be used to enhance the sensitivity of tumor cells to the therapeutic effect of cisplatin through the regulation of Nrf2/ARE signaling.
authors.affiliation: College of Pharmacy, CHA University, Seongnam, 463-836, Korea.
authors.forename: Juhee
authors.initials: J
authors.lastname: Lim
authors.forename: Sung Ho
authors.initials: SH
authors.lastname: Lee
authors.forename: Sera
authors.initials: S
authors.lastname: Cho
authors.forename: Ik-Soo
authors.initials: IS
authors.lastname: Lee
authors.forename: Bok Yun
authors.initials: BY
authors.lastname: Kang
authors.forename: Hyun Jin
authors.initials: HJ
authors.lastname: Choi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D047188:Chalcones / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D057809:HEK293 Cells; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D047188:Chalcones; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D017382:Reactive Oxygen Species; C097470:4'-methoxychalcone; D002945:Cisplatin
references.citation: Methods Mol Biol. 2010;647:37-74
references.pmid: 20694660
references.citation: Mol Cells. 2012 Jun;33(6):611-6
references.pmid: 22610366
references.citation: Eur J Med Chem. 2010 Jun;45(6):2206-13
references.pmid: 20153559
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1627-37
references.pmid: 20446773
references.citation: Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8
references.pmid: 21205897
references.citation: Lung Cancer. 2008 Apr;60(1):47-56
references.pmid: 18006113
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1713-48
references.pmid: 20446772
references.citation: Molecules. 2010 Aug 04;15(8):5336-53
references.pmid: 20714300
references.citation: Eur Arch Otorhinolaryngol. 2012 Dec;269(12):2455-9
references.pmid: 22584749
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1623-6
references.pmid: 20486759
references.citation: J Cell Biochem. 2011 Jun;112(6):1524-31
references.pmid: 21328610
references.citation: Clin Cancer Res. 2009 May 15;15(10):3423-32
references.pmid: 19417020
references.citation: Arch Toxicol. 2012 Aug;86(8):1233-50
references.pmid: 22382776
references.citation: Neurochem Int. 2011 Feb;58(2):153-60
references.pmid: 21093515
references.citation: Carcinogenesis. 2008 Jun;29(6):1235-43
references.pmid: 18413364
references.citation: Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):43-52
references.pmid: 16487036
references.citation: Carcinogenesis. 2010 Jan;31(1):90-9
references.pmid: 19793802
references.citation: Mol Cells. 2009 Oct 31;28(4):365-8
references.pmid: 19809799
references.citation: Exp Mol Med. 2012 Jun 30;44(6):369-77
references.pmid: 22382990
references.citation: J Biol Chem. 2006 Nov 3;281(44):33761-72
references.pmid: 16950787
references.citation: Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70
references.pmid: 18838122
references.citation: Food Chem Toxicol. 2012 Jul;50(7):2565-74
references.pmid: 22266358
references.citation: J Med Chem. 2012 Feb 9;55(3):1382-8
references.pmid: 22239485
references.citation: Free Radic Biol Med. 2009 Nov 1;47(9):1304-9
references.pmid: 19666107
references.citation: Chem Biol Interact. 2010 Oct 6;188(1):111-8
references.pmid: 20620131
references.citation: EMBO J. 1996 Dec 2;15(23):6541-51
references.pmid: 8978681
references.citation: Bioorg Med Chem Lett. 2010 Nov 15;20(22):6508-12
references.pmid: 20926293
references.citation: Int Immunopharmacol. 2011 Mar;11(3):295-309
references.pmid: 21184860
references.citation: Free Radic Biol Med. 2004 May 15;36(10):1199-207
references.pmid: 15110384
references.citation: Pharmacol Res. 2008 May;57(5):325-31
references.pmid: 18455424
references.citation: Nat Rev Cancer. 2012 Jul 19;12(8):564-71
references.pmid: 22810811
references.citation: Pharmacol Res. 2008 Feb;57(2):125-31
references.pmid: 18282716